NeoPharm CO., LTD.

KOSDAQ:A092730 Stock Report

Market Cap: ₩183.1b

NeoPharm Future Growth

Future criteria checks 3/6

NeoPharm is forecast to grow earnings and revenue by 18.1% and 15% per annum respectively. EPS is expected to grow by 16.5% per annum. Return on equity is forecast to be 15.6% in 3 years.

Key information

18.1%

Earnings growth rate

16.5%

EPS growth rate

Personal Products earnings growth8.8%
Revenue growth rate15.0%
Future return on equity15.6%
Analyst coverage

Low

Last updated15 Oct 2024

Recent future growth updates

Recent updates

We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising Earnings

Nov 20
We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising Earnings

The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire Confidence

Nov 13
The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire Confidence

NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors

Sep 13
NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors

NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends

Aug 07
NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends

NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Jun 13
NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

Apr 24
Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Mar 25
NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Mar 28
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Mar 15
What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

Mar 02
How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

We're Watching These Trends At NeoPharm (KOSDAQ:092730)

Feb 18
We're Watching These Trends At NeoPharm (KOSDAQ:092730)

We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

Feb 08
We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

Jan 26
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Jan 15
An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

Jan 04
Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24
NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Dec 15
What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Dec 04
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Nov 23
Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Earnings and Revenue Growth Forecasts

KOSDAQ:A092730 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026157,30033,75035,70035,7002
12/31/2025140,35029,40029,70029,7002
12/31/2024120,20024,70023,00023,0001
9/30/2024112,20022,334-6,38216,167N/A
6/30/2024107,85822,929-3,94117,678N/A
3/31/2024101,73522,516-1,80820,105N/A
12/31/202397,10523,2132,43523,263N/A
9/30/202392,27120,73322,96724,024N/A
6/30/202389,29219,78120,19921,423N/A
3/31/202386,27218,91218,96619,685N/A
12/31/202285,03317,02717,35418,161N/A
9/30/202286,80518,24517,37318,071N/A
6/30/202287,42417,37017,80918,258N/A
3/31/202287,32116,90518,77519,267N/A
12/31/202187,93117,71321,20321,681N/A
9/30/202186,80218,20720,32020,881N/A
6/30/202185,27518,05921,19021,766N/A
3/31/202185,28718,47418,83719,464N/A
12/31/202081,62518,13116,34317,074N/A
9/30/202081,41318,73411,30917,364N/A
6/30/202082,61819,93512,02818,544N/A
3/31/202082,68019,90116,90924,255N/A
12/31/201983,24019,24512,03019,224N/A
9/30/201979,61118,00215,24517,190N/A
6/30/201974,86316,67513,48815,234N/A
3/31/201969,50015,79510,16812,149N/A
12/31/201866,27515,37014,09616,179N/A
9/30/201863,14313,68211,35113,893N/A
6/30/201860,23613,105N/A14,629N/A
3/31/201857,17512,514N/A12,814N/A
12/31/201753,63411,559N/A10,646N/A
9/30/201749,7659,814N/A10,212N/A
6/30/201746,7399,365N/A9,866N/A
3/31/201743,1648,096N/A9,548N/A
12/31/201642,3697,742N/A9,157N/A
9/30/201643,0975,955N/A8,664N/A
6/30/201641,9995,419N/A6,471N/A
12/31/201535,9653,407N/A6,095N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A092730's forecast earnings growth (18.1% per year) is above the savings rate (2.7%).

Earnings vs Market: A092730's earnings (18.1% per year) are forecast to grow faster than the KR market (12.6% per year).

High Growth Earnings: A092730's earnings are forecast to grow, but not significantly.

Revenue vs Market: A092730's revenue (15% per year) is forecast to grow faster than the KR market (5.2% per year).

High Growth Revenue: A092730's revenue (15% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A092730's Return on Equity is forecast to be low in 3 years time (15.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 08:42
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NeoPharm CO., LTD. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Soo Min KangCape Investment & Securities Co., Ltd.
Jiseon AnDAOL Investment & Securities Co., Ltd.
Hyeon Jin ParkDB Financial Investment Co. Ltd.